Epidemiology and Natural History of Fibrostenosing Inflammatory Bowel Disease

  • Wee Khoon Ng
  • Siew C. NgEmail author


Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing inflammatory gastrointestinal diseases. CD frequently results in transmural inflammation and is more commonly associated with stricturing diseases compared with UC. Inflammation in UC is usually only limited to the mucosa and stricture formation in the colon occurs rarely. Strictures in IBD can be secondary to either inflammation or fibrosis and it is important to determine the aetiology to provide definitive treatment. Once strictures occur, they can be challenging to manage. Despite the advent of multiple new therapeutic agents for IBD, there has been no significant impact on the incidence and morbidity of strictures.


Crohn’s disease Ulcerative colitis Inflammatory bowel disease Strictures Inflammation Fibrosis Fibrostenosing 


  1. 1.
    Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42. quiz e30.CrossRefGoogle Scholar
  3. 3.
    Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14(2):111–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145(1):158–65 e2.CrossRefGoogle Scholar
  6. 6.
    The impact of inflammatory bowel disease in Canada. 2012 final report and recommendations. In: Canada CsaCFo, editor. 2012.Google Scholar
  7. 7.
    Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8(4):244–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49(6):777–82.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chang CW, Wong JM, Tung CC, Shih IL, Wang HY, Wei SC. Intestinal stricture in Crohn’s disease. Intest Res. 2015;13(1):19–26.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cleynen I, Gonzalez JR, Figueroa C, Franke A, McGovern D, Bortlik M, et al. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013;62(11):1556–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Yano Y, Matsui T, Hirai F, Okado Y, Sato Y, Tsurumi K, et al. Cancer risk in Japanese Crohn’s disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol. 2013;28(8):1300–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Wei SC, Ni YH, Yang HI, Su YN, Chang MC, Chang YT, et al. A hospital-based study of clinical and genetic features of Crohn’s disease. J Formos Med Assoc. 2011;110(9):600–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Ye BD, Yang SK, Cho YK, Park SH, Yang DH, Yoon SM, et al. Clinical features and long-term prognosis of Crohn’s disease in Korea. Scand J Gastroenterol. 2010;45(10):1178–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33(7):938–41.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    De Dombal FT, Watts JM, Watkinson G, Goligher JC. Local complications of ulcerative colitis: stricture, pseudopolyposis, and carcinoma of colon and rectum. Br Med J. 1966;1(5501):1442–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hunt RH, Teague RH, Swarbrick ET, Williams CB. Colonoscopy in management of colonic strictures. Br Med J. 1975;3(5979):360–1.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Marshak RH, Bloch C, Wolf BS. The roentgen findings in strictures of the Colon associated with ulcerative and granulomatous colitis. Am J Roentgenol Radium Therapy, Nucl Med. 1963;90:709–16.Google Scholar
  18. 18.
    Warren S, Sommers SC. Pathogenesis of ulcerative colitis. Am J Pathol. 1949;25(4):657–79.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lashner BA, Turner BC, Bostwick DG, Frank PH, Hanauer SB. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990;35(3):349–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1964;5:1–22.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Burke JP, Mulsow JJ, O’Keane C, Docherty NG, Watson RW, O’Connell PR. Fibrogenesis in Crohn’s disease. Am J Gastroenterol. 2007;102(2):439–48.CrossRefPubMedGoogle Scholar
  22. 22.
    Hugot JP. Genetic origin of IBD. Inflamm Bowel Dis. 2004;10(Suppl 1):S11–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature. 1996;379(6568):821–3.CrossRefPubMedGoogle Scholar
  24. 24.
    Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979–86.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tung CC, Wong JM, Lee WC, Liu HH, Chang CH, Chang MC, et al. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn’s disease. J Gastroenterol Hepatol. 2014;29(4):723–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62(7):1072–84.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chow DK, Leong RW, Lai LH, Wong GL, Leung WK, Chan FK, et al. Changes in Crohn’s disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm Bowel Dis. 2008;14(4):536–41.CrossRefPubMedGoogle Scholar
  28. 28.
    Oriuchi T, Hiwatashi N, Kinouchi Y, Takahashi S, Takagi S, Negoro K, et al. Clinical course and longterm prognosis of Japanese patients with Crohn’s disease: predictive factors, rates of operation, and mortality. J Gastroenterol. 2003;38(10):942–53.CrossRefPubMedGoogle Scholar
  29. 29.
    Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008;14(4):542–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013;28(7):1148–53.CrossRefPubMedGoogle Scholar
  31. 31.
    Papi C, Festa V, Fagnani C, Stazi A, Antonelli G, Moretti A, et al. Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. Dig Liver Dis. 2005;37(4):247–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Vatn MH. Natural history and complications of IBD. Curr Gastroenterol Rep. 2009;11(6):481–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130(3):650–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30(7):699–706.CrossRefPubMedGoogle Scholar
  35. 35.
    Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut. 2005;54(2):237–41.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4(1):28–62.CrossRefPubMedGoogle Scholar
  38. 38.
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255–60.CrossRefPubMedGoogle Scholar
  39. 39.
    Latella G, Caprilli R, Travis S. In favour of early surgery in Crohn’s disease: a hypothesis to be tested. J Crohns Colitis. 2011;5(1):1–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Spinelli A, Correale C, Szabo H, Montorsi M. Intestinal fibrosis in Crohn’s disease: medical treatment or surgery? Curr Drug Targets. 2010;11(2):242–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4(1):63–101.CrossRefPubMedGoogle Scholar
  42. 42.
    Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn’s disease strictures. Inflamm Bowel Dis. 2004;10(1):55–60.CrossRefPubMedGoogle Scholar
  43. 43.
    Samimi R, Flasar MH, Kavic S, Tracy K, Cross RK. Outcome of medical treatment of stricturing and penetrating Crohn’s disease: a retrospective study. Inflamm Bowel Dis. 2010;16(7):1187–94.CrossRefPubMedGoogle Scholar
  44. 44.
    Swan NC, Geoghegan JG, O’Donoghue DP, Hyland JM, Sheahan K. Fulminant colitis in inflammatory bowel disease: detailed pathologic and clinical analysis. Dis Colon Rectum. 1998;41(12):1511–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Yamagata M, Mikami T, Tsuruta T, Yokoyama K, Sada M, Kobayashi K, et al. Submucosal fibrosis and basic-fibroblast growth factor-positive neutrophils correlate with colonic stenosis in cases of ulcerative colitis. Digestion. 2011;84(1):12–21.CrossRefPubMedGoogle Scholar
  46. 46.
    Yantiss RK, Farraye FA, O’Brien MJ, Fruin AB, Stucchi AF, Becker JM, et al. Prognostic significance of superficial fissuring ulceration in patients with severe “indeterminate” colitis. Am J Surg Pathol. 2006;30(2):165–70.CrossRefPubMedGoogle Scholar
  47. 47.
    Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology. 2006;48(2):116–32.CrossRefPubMedGoogle Scholar
  48. 48.
    Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012;18(29):3790–9.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lennard-Jones JE, Lockhart-Mummery HE, Morson BC. Clinical and pathological differentiation of Crohn’s disease and proctocolitis. Gastroenterology. 1968;54(6):1162–70.PubMedGoogle Scholar
  50. 50.
    Sparberg M, Fennessy J, Kirsner JB. Ulcerative proctitis and mild ulcerative colitis: a study of 220 patients. Medicine (Baltimore). 1966;45(5):391–412.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Gastroenterology and HepatologyTan Tock Seng HospitalSingaporeSingapore
  2. 2.Department of Medicine and TherapeuticsInstitute of Digestive Disease, State Key Laboratory of Digestive Diseases, LKS Institute of Health Science, Chinese University of Hong KongHong KongChina

Personalised recommendations